HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

lavendamycin

from Streptomyces lavendulae; structure given in first source

Also Known As:

9H-Pyrido(3,4-b)indole-3-carboxylic acid, 1-(7-amino-5,8-dihydro-5,8-dioxo-2-quinolinyl)-4-methyl-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Picolinic Acids: 1
      - Streptonigrin: 88
        lavendamycin: 2
- Heterocyclic Acids
  - Picolinic Acids: 1
    - Streptonigrin: 88
      - lavendamycin: 2

Experts

1.	Abbott, Geoffrey: 1 article (05/2013)
2.	Beall, Howard D: 1 article (05/2013)
3.	Diaz, Philippe: 1 article (05/2013)
4.	Duncan, Nathan S: 1 article (05/2013)
5.	Eickholt, Emily A: 1 article (05/2013)
6.	Kearns, Alison K: 1 article (05/2013)
7.	Keyari, Charles M: 1 article (05/2013)

Related Diseases

1.	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 10/01/2023 - "We identified three low-molecular-weight compounds (auxarconjugatin-B, rumbrin, and lavendamycin) that inhibited the proliferation of the T-ALL cell line CCRF-CEM, but not that of the B lymphoma cell line Raji in a low concentration range. "
2.	Lymphoma (Lymphomas) 10/01/2023 - "We identified three low-molecular-weight compounds (auxarconjugatin-B, rumbrin, and lavendamycin) that inhibited the proliferation of the T-ALL cell line CCRF-CEM, but not that of the B lymphoma cell line Raji in a low concentration range. "
3.	Breast Neoplasms (Breast Cancer) 05/23/2013 - "Compound 22 showed potent activity against human breast cancer cells expressing or not expressing NQO1, with respective IC50 values of 190 nM and 140 nM and a low NQO1-mediated reduction rate, which suggests that the mode of action of 22 differs from that of lavendamycin and involves an unidentified target(s)."

Related Drugs and Biologics

1.	rumbrin